We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > endocyte

News List

Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion pharmafocusasia
November 28, 2018
Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that it has entered into an agreement .....
Novartis to acquire US cancer drug developer Endocyte for $2.1bn pharmaceutical-technology
October 22, 2018
The completion of the acquisition is conditional on customary closing conditions, including shareholder approval and regulatory approvals.
Novartis snaps up cancer drug developer Endocyte for $2.1 billion pharmafile
October 19, 2018
Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology to investigate potential development of therapies in prostate cancer, it has emerged.
Novartis buys Endocyte for $2.1 billion pharmatimes
October 19, 2018
Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”.
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177 firstwordpharma
July 10, 2018
WEST LAFAYETTE, Ind. & GARCHING, Germany--(BUSINESS WIRE)-- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM)